Brad Loncar
Entrepreneur, investor w/ a #biotech focus, avid reader, KC native, alumnus of @univmiami. 👻: bradloncar
Last synced from Twitter 9m ago
CASI Pharmaceuticals | CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Brad Loncar
I met with CASI when I was in Beijing a couple of months ago. They've been busy since then...Chairman becomes CEO, acquired a CD38 inhibitor, launched Evomela, and now getting into cell therapy.
30h
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
CAMBRIDGE, Mass. and BEIJING, China , June 17, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and...
Brad Loncar
The thing about this PD-1 is that it truly might be differentiated and maybe even better than the crowd because it is engineered to minimize Fc gamma receptor binding. Will be ironic if it ends up being better than Opdivo one day.
31h
Pfizer to Acquire Array BioPharma
—Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term —Opportunity to strengthen category leadership in Oncology with the addition of a...
Chem teacher behind pharmaceutical firm to be China’s third-richest woman
Zhong Huijuan will have US$7.9 billion fortune after her Hansoh Pharmaceutical Group goes public in Hong Kong on Friday
Brad Loncar
Hansoh begins trading in HK later this morning. This is a big one. $10B+ market value.
5d
FTC demands could mean months-long delay for Roche-Spark deal
A rare "second request" for info on Roche's cash buyout burdens both companies with extensive document demands and executive testimony.
Temasek-backed Tessa Therapeutics inks $120m oncology JV with China's CSGKC
CSGKC will invest $80 million while Tessa will contribute $40 million to the JV.
Industry Focus - Motley Fool Podcasts
Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at [email protected]
Drug to Replace Chemotherapy May Reshape Cancer Care
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care.
Biden promises he'll cure cancer if elected president
Joe Biden told an audience in Ottumwa, Iowa Tuesday that his White House would "cure" cancer should he beat President Trump in 2020.
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
FDA approves chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc.
1
Brad Loncar
FTC has asked Roche and Spark for more info and they announce yet another extension of the deal.
9d
Elliott Management to acquire Barnes & Noble for $683 million
Elliott, the firm founded and led by billionaire Paul Singer, acquired Britain's biggest bookseller, Waterstones, last year. Owning the two book retailing giants could give Elliott synergies and buying leverage with publishers.
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics
The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
2
Brad Loncar
$VRTX expanding into DMD with $CRSP. $175M u/f to CRISPR. Also acquiring Exonics for $245M.
12d
GRAIL | GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments
— Hans Bishop, GRAIL Board Member and Former CEO of Juno Therapeutics, Will Succeed Jennifer Cook — — Joshua Ofman Appointed as Chief of Corporate Strategy and External Affairs — — Maykin Ho…
Commentary: Shining a light on shorts will improve market integrity, investor protection
The lack of transparency in short-selling positions leads to speculation about shorting activities and limits engagement with investors.
Hong Kong gives biotech a chance
After difficult years, new policies are helping a biotech sector bloom in the trading and banking hub
China’s New Cancer Drugs Are Much Cheaper Than Their U.S. Rivals
One way to realize Beijing’s dreams of a world-class pharmaceutical industry: Low prices.
Amgen drug shrank tumors in patients with 'undruggable' cancer protein
Discovering drugs capable of blocking KRAS has proven difficult. The protein is spherical and nearly featureless — like that of a tennis ball.